Author:
Ashe Karen M.,Budman Eva,Bangari Dinesh S.,Siegel Craig S.,Nietupski Jennifer B.,Wang Bing,Desnick Robert J.,Scheule Ronald K.,Leonard John P.,Cheng Seng H.,Marshall John
Publisher
Springer Science and Business Media LLC
Subject
Genetics(clinical),Genetics,Molecular Biology,Molecular Medicine
Reference44 articles.
1. Desnick RJ, Ioannou YA, Eng CM. 150: α-Galactosidase A Deficiency: Fabry Disease. In: The Online Metabolic and Molecular Bases of Inherited Disease [Internet]. Valle D, et al. (eds.) McGraw-Hill, [New York]. Available from: https://doi.org/ommbid.mhmedical.com/content.aspx?bookid=474§ionid=45374153
2. Schiffmann R, Ries M, Timmons M, Flaherty JT, Brady RO. (2006) Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol. Dial. Transplant. 21:345–354.
3. Germain DP, et al. (2007) Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J. Am. Soc. Nephrol. 18:1547–1557.
4. Banikazemi M, et al. (2007) Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann. Intern. Med. 146:77–86.
5. Wilcox WR, et al. (2004) Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am. J. Hum. Genet. 75:65–74.
Cited by
75 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献